by A recent study, spearheaded by Junqing Xie, a Postdoctoral Researcher in Pharmacoepidemiology and Pharmacogenetics at NDORMS, delved into the relationship between genetic variations in the Human Leukocyte Antigen (HLA) genes and the immune response to COVID-19 vaccines.
HLA genes are pivotal in the immune system’s recognition and response to foreign substances, including viruses. Previous research has demonstrated their significance in the context of other vaccines, such as hepatitis B, measles, and influenza.
The researchers analyzed data from over 368,000 individuals who had received a COVID-19 vaccination, with a subgroup of 194,371 participants having their antibody levels measured. The study confirmed earlier findings that specific genetic variations, notably in the HLA-DQB1*06 gene, are linked to enhanced Monoclonal Antibody Therapeutics responses to COVID-19 vaccines.
However, the team’s findings revealed that while the DQB1*06 variant bolsters antibody production, it does not definitively support the notion that this alone can substantially decrease the risk of COVID-19 infection in the general population. This evidence underscores the importance of recognizing that antibody levels alone do not provide a comprehensive understanding of vaccine effectiveness.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
